Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM IODIDE I 123.
IODOHIPPURATE SODIUM I 131 vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical